Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013–2014)

A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372 Stenotrophomonas maltophilia were collected from Western Europe (WEU; n =10,021), Eastern Europe (EEU; n =4957), and the Asia-Pacific region (APAC; n =3408 [1052 from China...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Pfaller, M.A. [verfasserIn] Flamm, R.K. Duncan, L.R. Mendes, R.E. Jones, R.N. Sader, H.S.

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2017transfer abstract

Umfang:	7

Übergeordnetes Werk:	Enthalten in: Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications - Rodrigues, Jéssica S. ELSEVIER, 2023, Amsterdam [u.a.]
Übergeordnetes Werk:	volume:88 ; year:2017 ; number:2 ; pages:177-183 ; extent:7

Links:	Volltext

DOI / URN:	10.1016/j.diagmicrobio.2017.02.020

Katalog-ID:	ELV03593039X

Internformat


LEADER	01000caa a22002652 4500
001	ELV03593039X
003	DE-627
005	20230625210057.0
007	cr uuu---uuuuu
008	180603s2017 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.diagmicrobio.2017.02.020 \|2 doi
028	5	2	\|a GBVA2017012000021.pica
035			\|a (DE-627)ELV03593039X
035			\|a (ELSEVIER)S0732-8893(17)30076-7
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0		\|a 610
082	0	4	\|a 610 \|q DE-600
082	0	4	\|a 540 \|a 570 \|q VZ
084			\|a BIODIV \|q DE-30 \|2 fid
084			\|a 35.80 \|2 bkl
084			\|a 58.30 \|2 bkl
100	1		\|a Pfaller, M.A. \|e verfasserin \|4 aut
245	1	0	\|a Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013–2014)
264		1	\|c 2017transfer abstract
300			\|a 7
336			\|a nicht spezifiziert \|b zzz \|2 rdacontent
337			\|a nicht spezifiziert \|b z \|2 rdamedia
338			\|a nicht spezifiziert \|b zu \|2 rdacarrier
520			\|a A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372 Stenotrophomonas maltophilia were collected from Western Europe (WEU; n =10,021), Eastern Europe (EEU; n =4957), and the Asia-Pacific region (APAC; n =3408 [1052 from China]) in 2013–2014 as part of the SENTRY Antimicrobial Surveillance Program and tested by a reference broth microdilution method for susceptibility against tigecycline, cefoperazone/sulbactam, and comparator agents. Overall, 95.3% of Enterobacteriaceae were susceptible (≤1μg/mL; EUCAST) to tigecycline (MIC50/90, 0.12/1μg/mL) with regional EUCAST susceptibility rates of 94.8–97.8% (98.9–99.6% inhibited at ≤2μg/mL [US FDA]). Among Acinetobacter spp., 66.1% (EEU) and 79.5% (WEU) were inhibited at ≤1μg/mL of tigecycline (94.9% and 97.3% inhibited at ≤2μg/mL; pan-European MIC50/90, 1/2μg/mL). For S. maltophilia, 65.4% (China) to 88.9% (EEU) of the isolates were inhibited at ≤1μg/mL of tigecycline. Cefoperazone/sulbactam inhibited 94.6/83.5/91.5% of Enterobacteriaceae at ≤16μg/mL in WEU/EEU/APAC, respectively.
520			\|a A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372 Stenotrophomonas maltophilia were collected from Western Europe (WEU; n =10,021), Eastern Europe (EEU; n =4957), and the Asia-Pacific region (APAC; n =3408 [1052 from China]) in 2013–2014 as part of the SENTRY Antimicrobial Surveillance Program and tested by a reference broth microdilution method for susceptibility against tigecycline, cefoperazone/sulbactam, and comparator agents. Overall, 95.3% of Enterobacteriaceae were susceptible (≤1μg/mL; EUCAST) to tigecycline (MIC50/90, 0.12/1μg/mL) with regional EUCAST susceptibility rates of 94.8–97.8% (98.9–99.6% inhibited at ≤2μg/mL [US FDA]). Among Acinetobacter spp., 66.1% (EEU) and 79.5% (WEU) were inhibited at ≤1μg/mL of tigecycline (94.9% and 97.3% inhibited at ≤2μg/mL; pan-European MIC50/90, 1/2μg/mL). For S. maltophilia, 65.4% (China) to 88.9% (EEU) of the isolates were inhibited at ≤1μg/mL of tigecycline. Cefoperazone/sulbactam inhibited 94.6/83.5/91.5% of Enterobacteriaceae at ≤16μg/mL in WEU/EEU/APAC, respectively.
700	1		\|a Flamm, R.K. \|4 oth
700	1		\|a Duncan, L.R. \|4 oth
700	1		\|a Mendes, R.E. \|4 oth
700	1		\|a Jones, R.N. \|4 oth
700	1		\|a Sader, H.S. \|4 oth
773	0	8	\|i Enthalten in \|n Elsevier Science \|a Rodrigues, Jéssica S. ELSEVIER \|t Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications \|d 2023 \|g Amsterdam [u.a.] \|w (DE-627)ELV009877355
773	1	8	\|g volume:88 \|g year:2017 \|g number:2 \|g pages:177-183 \|g extent:7
856	4	0	\|u https://doi.org/10.1016/j.diagmicrobio.2017.02.020 \|3 Volltext
912			\|a GBV_USEFLAG_U
912			\|a GBV_ELV
912			\|a SYSFLAG_U
912			\|a FID-BIODIV
912			\|a SSG-OLC-PHA
936	b	k	\|a 35.80 \|j Makromolekulare Chemie \|q VZ
936	b	k	\|a 58.30 \|j Biotechnologie \|q VZ
951			\|a AR
952			\|d 88 \|j 2017 \|e 2 \|h 177-183 \|g 7
953			\|2 045F \|a 610

Indexfelder

author_variant	m p mp
matchkey_str	pfallermaflammrkduncanlrmendesrejonesrns:2017----:niirbaatvtotgcciencfprznslatmetdgis136rmeaieraimfoe
hierarchy_sort_str	2017transfer abstract
bklnumber	35.80 58.30
publishDate	2017
allfields	10.1016/j.diagmicrobio.2017.02.020 doi GBVA2017012000021.pica (DE-627)ELV03593039X (ELSEVIER)S0732-8893(17)30076-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 570 VZ BIODIV DE-30 fid 35.80 bkl 58.30 bkl Pfaller, M.A. verfasserin aut Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013–2014) 2017transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372 Stenotrophomonas maltophilia were collected from Western Europe (WEU; n =10,021), Eastern Europe (EEU; n =4957), and the Asia-Pacific region (APAC; n =3408 [1052 from China]) in 2013–2014 as part of the SENTRY Antimicrobial Surveillance Program and tested by a reference broth microdilution method for susceptibility against tigecycline, cefoperazone/sulbactam, and comparator agents. Overall, 95.3% of Enterobacteriaceae were susceptible (≤1μg/mL; EUCAST) to tigecycline (MIC50/90, 0.12/1μg/mL) with regional EUCAST susceptibility rates of 94.8–97.8% (98.9–99.6% inhibited at ≤2μg/mL [US FDA]). Among Acinetobacter spp., 66.1% (EEU) and 79.5% (WEU) were inhibited at ≤1μg/mL of tigecycline (94.9% and 97.3% inhibited at ≤2μg/mL; pan-European MIC50/90, 1/2μg/mL). For S. maltophilia, 65.4% (China) to 88.9% (EEU) of the isolates were inhibited at ≤1μg/mL of tigecycline. Cefoperazone/sulbactam inhibited 94.6/83.5/91.5% of Enterobacteriaceae at ≤16μg/mL in WEU/EEU/APAC, respectively. A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372 Stenotrophomonas maltophilia were collected from Western Europe (WEU; n =10,021), Eastern Europe (EEU; n =4957), and the Asia-Pacific region (APAC; n =3408 [1052 from China]) in 2013–2014 as part of the SENTRY Antimicrobial Surveillance Program and tested by a reference broth microdilution method for susceptibility against tigecycline, cefoperazone/sulbactam, and comparator agents. Overall, 95.3% of Enterobacteriaceae were susceptible (≤1μg/mL; EUCAST) to tigecycline (MIC50/90, 0.12/1μg/mL) with regional EUCAST susceptibility rates of 94.8–97.8% (98.9–99.6% inhibited at ≤2μg/mL [US FDA]). Among Acinetobacter spp., 66.1% (EEU) and 79.5% (WEU) were inhibited at ≤1μg/mL of tigecycline (94.9% and 97.3% inhibited at ≤2μg/mL; pan-European MIC50/90, 1/2μg/mL). For S. maltophilia, 65.4% (China) to 88.9% (EEU) of the isolates were inhibited at ≤1μg/mL of tigecycline. Cefoperazone/sulbactam inhibited 94.6/83.5/91.5% of Enterobacteriaceae at ≤16μg/mL in WEU/EEU/APAC, respectively. Flamm, R.K. oth Duncan, L.R. oth Mendes, R.E. oth Jones, R.N. oth Sader, H.S. oth Enthalten in Elsevier Science Rodrigues, Jéssica S. ELSEVIER Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications 2023 Amsterdam [u.a.] (DE-627)ELV009877355 volume:88 year:2017 number:2 pages:177-183 extent:7 https://doi.org/10.1016/j.diagmicrobio.2017.02.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.80 Makromolekulare Chemie VZ 58.30 Biotechnologie VZ AR 88 2017 2 177-183 7 045F 610
spelling	10.1016/j.diagmicrobio.2017.02.020 doi GBVA2017012000021.pica (DE-627)ELV03593039X (ELSEVIER)S0732-8893(17)30076-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 570 VZ BIODIV DE-30 fid 35.80 bkl 58.30 bkl Pfaller, M.A. verfasserin aut Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013–2014) 2017transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372 Stenotrophomonas maltophilia were collected from Western Europe (WEU; n =10,021), Eastern Europe (EEU; n =4957), and the Asia-Pacific region (APAC; n =3408 [1052 from China]) in 2013–2014 as part of the SENTRY Antimicrobial Surveillance Program and tested by a reference broth microdilution method for susceptibility against tigecycline, cefoperazone/sulbactam, and comparator agents. Overall, 95.3% of Enterobacteriaceae were susceptible (≤1μg/mL; EUCAST) to tigecycline (MIC50/90, 0.12/1μg/mL) with regional EUCAST susceptibility rates of 94.8–97.8% (98.9–99.6% inhibited at ≤2μg/mL [US FDA]). Among Acinetobacter spp., 66.1% (EEU) and 79.5% (WEU) were inhibited at ≤1μg/mL of tigecycline (94.9% and 97.3% inhibited at ≤2μg/mL; pan-European MIC50/90, 1/2μg/mL). For S. maltophilia, 65.4% (China) to 88.9% (EEU) of the isolates were inhibited at ≤1μg/mL of tigecycline. Cefoperazone/sulbactam inhibited 94.6/83.5/91.5% of Enterobacteriaceae at ≤16μg/mL in WEU/EEU/APAC, respectively. A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372 Stenotrophomonas maltophilia were collected from Western Europe (WEU; n =10,021), Eastern Europe (EEU; n =4957), and the Asia-Pacific region (APAC; n =3408 [1052 from China]) in 2013–2014 as part of the SENTRY Antimicrobial Surveillance Program and tested by a reference broth microdilution method for susceptibility against tigecycline, cefoperazone/sulbactam, and comparator agents. Overall, 95.3% of Enterobacteriaceae were susceptible (≤1μg/mL; EUCAST) to tigecycline (MIC50/90, 0.12/1μg/mL) with regional EUCAST susceptibility rates of 94.8–97.8% (98.9–99.6% inhibited at ≤2μg/mL [US FDA]). Among Acinetobacter spp., 66.1% (EEU) and 79.5% (WEU) were inhibited at ≤1μg/mL of tigecycline (94.9% and 97.3% inhibited at ≤2μg/mL; pan-European MIC50/90, 1/2μg/mL). For S. maltophilia, 65.4% (China) to 88.9% (EEU) of the isolates were inhibited at ≤1μg/mL of tigecycline. Cefoperazone/sulbactam inhibited 94.6/83.5/91.5% of Enterobacteriaceae at ≤16μg/mL in WEU/EEU/APAC, respectively. Flamm, R.K. oth Duncan, L.R. oth Mendes, R.E. oth Jones, R.N. oth Sader, H.S. oth Enthalten in Elsevier Science Rodrigues, Jéssica S. ELSEVIER Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications 2023 Amsterdam [u.a.] (DE-627)ELV009877355 volume:88 year:2017 number:2 pages:177-183 extent:7 https://doi.org/10.1016/j.diagmicrobio.2017.02.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.80 Makromolekulare Chemie VZ 58.30 Biotechnologie VZ AR 88 2017 2 177-183 7 045F 610
allfields_unstemmed	10.1016/j.diagmicrobio.2017.02.020 doi GBVA2017012000021.pica (DE-627)ELV03593039X (ELSEVIER)S0732-8893(17)30076-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 570 VZ BIODIV DE-30 fid 35.80 bkl 58.30 bkl Pfaller, M.A. verfasserin aut Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013–2014) 2017transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372 Stenotrophomonas maltophilia were collected from Western Europe (WEU; n =10,021), Eastern Europe (EEU; n =4957), and the Asia-Pacific region (APAC; n =3408 [1052 from China]) in 2013–2014 as part of the SENTRY Antimicrobial Surveillance Program and tested by a reference broth microdilution method for susceptibility against tigecycline, cefoperazone/sulbactam, and comparator agents. Overall, 95.3% of Enterobacteriaceae were susceptible (≤1μg/mL; EUCAST) to tigecycline (MIC50/90, 0.12/1μg/mL) with regional EUCAST susceptibility rates of 94.8–97.8% (98.9–99.6% inhibited at ≤2μg/mL [US FDA]). Among Acinetobacter spp., 66.1% (EEU) and 79.5% (WEU) were inhibited at ≤1μg/mL of tigecycline (94.9% and 97.3% inhibited at ≤2μg/mL; pan-European MIC50/90, 1/2μg/mL). For S. maltophilia, 65.4% (China) to 88.9% (EEU) of the isolates were inhibited at ≤1μg/mL of tigecycline. Cefoperazone/sulbactam inhibited 94.6/83.5/91.5% of Enterobacteriaceae at ≤16μg/mL in WEU/EEU/APAC, respectively. A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372 Stenotrophomonas maltophilia were collected from Western Europe (WEU; n =10,021), Eastern Europe (EEU; n =4957), and the Asia-Pacific region (APAC; n =3408 [1052 from China]) in 2013–2014 as part of the SENTRY Antimicrobial Surveillance Program and tested by a reference broth microdilution method for susceptibility against tigecycline, cefoperazone/sulbactam, and comparator agents. Overall, 95.3% of Enterobacteriaceae were susceptible (≤1μg/mL; EUCAST) to tigecycline (MIC50/90, 0.12/1μg/mL) with regional EUCAST susceptibility rates of 94.8–97.8% (98.9–99.6% inhibited at ≤2μg/mL [US FDA]). Among Acinetobacter spp., 66.1% (EEU) and 79.5% (WEU) were inhibited at ≤1μg/mL of tigecycline (94.9% and 97.3% inhibited at ≤2μg/mL; pan-European MIC50/90, 1/2μg/mL). For S. maltophilia, 65.4% (China) to 88.9% (EEU) of the isolates were inhibited at ≤1μg/mL of tigecycline. Cefoperazone/sulbactam inhibited 94.6/83.5/91.5% of Enterobacteriaceae at ≤16μg/mL in WEU/EEU/APAC, respectively. Flamm, R.K. oth Duncan, L.R. oth Mendes, R.E. oth Jones, R.N. oth Sader, H.S. oth Enthalten in Elsevier Science Rodrigues, Jéssica S. ELSEVIER Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications 2023 Amsterdam [u.a.] (DE-627)ELV009877355 volume:88 year:2017 number:2 pages:177-183 extent:7 https://doi.org/10.1016/j.diagmicrobio.2017.02.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.80 Makromolekulare Chemie VZ 58.30 Biotechnologie VZ AR 88 2017 2 177-183 7 045F 610
allfieldsGer	10.1016/j.diagmicrobio.2017.02.020 doi GBVA2017012000021.pica (DE-627)ELV03593039X (ELSEVIER)S0732-8893(17)30076-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 570 VZ BIODIV DE-30 fid 35.80 bkl 58.30 bkl Pfaller, M.A. verfasserin aut Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013–2014) 2017transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372 Stenotrophomonas maltophilia were collected from Western Europe (WEU; n =10,021), Eastern Europe (EEU; n =4957), and the Asia-Pacific region (APAC; n =3408 [1052 from China]) in 2013–2014 as part of the SENTRY Antimicrobial Surveillance Program and tested by a reference broth microdilution method for susceptibility against tigecycline, cefoperazone/sulbactam, and comparator agents. Overall, 95.3% of Enterobacteriaceae were susceptible (≤1μg/mL; EUCAST) to tigecycline (MIC50/90, 0.12/1μg/mL) with regional EUCAST susceptibility rates of 94.8–97.8% (98.9–99.6% inhibited at ≤2μg/mL [US FDA]). Among Acinetobacter spp., 66.1% (EEU) and 79.5% (WEU) were inhibited at ≤1μg/mL of tigecycline (94.9% and 97.3% inhibited at ≤2μg/mL; pan-European MIC50/90, 1/2μg/mL). For S. maltophilia, 65.4% (China) to 88.9% (EEU) of the isolates were inhibited at ≤1μg/mL of tigecycline. Cefoperazone/sulbactam inhibited 94.6/83.5/91.5% of Enterobacteriaceae at ≤16μg/mL in WEU/EEU/APAC, respectively. A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372 Stenotrophomonas maltophilia were collected from Western Europe (WEU; n =10,021), Eastern Europe (EEU; n =4957), and the Asia-Pacific region (APAC; n =3408 [1052 from China]) in 2013–2014 as part of the SENTRY Antimicrobial Surveillance Program and tested by a reference broth microdilution method for susceptibility against tigecycline, cefoperazone/sulbactam, and comparator agents. Overall, 95.3% of Enterobacteriaceae were susceptible (≤1μg/mL; EUCAST) to tigecycline (MIC50/90, 0.12/1μg/mL) with regional EUCAST susceptibility rates of 94.8–97.8% (98.9–99.6% inhibited at ≤2μg/mL [US FDA]). Among Acinetobacter spp., 66.1% (EEU) and 79.5% (WEU) were inhibited at ≤1μg/mL of tigecycline (94.9% and 97.3% inhibited at ≤2μg/mL; pan-European MIC50/90, 1/2μg/mL). For S. maltophilia, 65.4% (China) to 88.9% (EEU) of the isolates were inhibited at ≤1μg/mL of tigecycline. Cefoperazone/sulbactam inhibited 94.6/83.5/91.5% of Enterobacteriaceae at ≤16μg/mL in WEU/EEU/APAC, respectively. Flamm, R.K. oth Duncan, L.R. oth Mendes, R.E. oth Jones, R.N. oth Sader, H.S. oth Enthalten in Elsevier Science Rodrigues, Jéssica S. ELSEVIER Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications 2023 Amsterdam [u.a.] (DE-627)ELV009877355 volume:88 year:2017 number:2 pages:177-183 extent:7 https://doi.org/10.1016/j.diagmicrobio.2017.02.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.80 Makromolekulare Chemie VZ 58.30 Biotechnologie VZ AR 88 2017 2 177-183 7 045F 610
allfieldsSound	10.1016/j.diagmicrobio.2017.02.020 doi GBVA2017012000021.pica (DE-627)ELV03593039X (ELSEVIER)S0732-8893(17)30076-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 570 VZ BIODIV DE-30 fid 35.80 bkl 58.30 bkl Pfaller, M.A. verfasserin aut Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013–2014) 2017transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372 Stenotrophomonas maltophilia were collected from Western Europe (WEU; n =10,021), Eastern Europe (EEU; n =4957), and the Asia-Pacific region (APAC; n =3408 [1052 from China]) in 2013–2014 as part of the SENTRY Antimicrobial Surveillance Program and tested by a reference broth microdilution method for susceptibility against tigecycline, cefoperazone/sulbactam, and comparator agents. Overall, 95.3% of Enterobacteriaceae were susceptible (≤1μg/mL; EUCAST) to tigecycline (MIC50/90, 0.12/1μg/mL) with regional EUCAST susceptibility rates of 94.8–97.8% (98.9–99.6% inhibited at ≤2μg/mL [US FDA]). Among Acinetobacter spp., 66.1% (EEU) and 79.5% (WEU) were inhibited at ≤1μg/mL of tigecycline (94.9% and 97.3% inhibited at ≤2μg/mL; pan-European MIC50/90, 1/2μg/mL). For S. maltophilia, 65.4% (China) to 88.9% (EEU) of the isolates were inhibited at ≤1μg/mL of tigecycline. Cefoperazone/sulbactam inhibited 94.6/83.5/91.5% of Enterobacteriaceae at ≤16μg/mL in WEU/EEU/APAC, respectively. A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372 Stenotrophomonas maltophilia were collected from Western Europe (WEU; n =10,021), Eastern Europe (EEU; n =4957), and the Asia-Pacific region (APAC; n =3408 [1052 from China]) in 2013–2014 as part of the SENTRY Antimicrobial Surveillance Program and tested by a reference broth microdilution method for susceptibility against tigecycline, cefoperazone/sulbactam, and comparator agents. Overall, 95.3% of Enterobacteriaceae were susceptible (≤1μg/mL; EUCAST) to tigecycline (MIC50/90, 0.12/1μg/mL) with regional EUCAST susceptibility rates of 94.8–97.8% (98.9–99.6% inhibited at ≤2μg/mL [US FDA]). Among Acinetobacter spp., 66.1% (EEU) and 79.5% (WEU) were inhibited at ≤1μg/mL of tigecycline (94.9% and 97.3% inhibited at ≤2μg/mL; pan-European MIC50/90, 1/2μg/mL). For S. maltophilia, 65.4% (China) to 88.9% (EEU) of the isolates were inhibited at ≤1μg/mL of tigecycline. Cefoperazone/sulbactam inhibited 94.6/83.5/91.5% of Enterobacteriaceae at ≤16μg/mL in WEU/EEU/APAC, respectively. Flamm, R.K. oth Duncan, L.R. oth Mendes, R.E. oth Jones, R.N. oth Sader, H.S. oth Enthalten in Elsevier Science Rodrigues, Jéssica S. ELSEVIER Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications 2023 Amsterdam [u.a.] (DE-627)ELV009877355 volume:88 year:2017 number:2 pages:177-183 extent:7 https://doi.org/10.1016/j.diagmicrobio.2017.02.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.80 Makromolekulare Chemie VZ 58.30 Biotechnologie VZ AR 88 2017 2 177-183 7 045F 610
language	English
source	Enthalten in Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications Amsterdam [u.a.] volume:88 year:2017 number:2 pages:177-183 extent:7
sourceStr	Enthalten in Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications Amsterdam [u.a.] volume:88 year:2017 number:2 pages:177-183 extent:7
format_phy_str_mv	Article
bklname	Makromolekulare Chemie Biotechnologie
institution	findex.gbv.de
dewey-raw	610
isfreeaccess_bool	false
container_title	Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications
authorswithroles_txt_mv	Pfaller, M.A. @@aut@@ Flamm, R.K. @@oth@@ Duncan, L.R. @@oth@@ Mendes, R.E. @@oth@@ Jones, R.N. @@oth@@ Sader, H.S. @@oth@@
publishDateDaySort_date	2017-01-01T00:00:00Z
hierarchy_top_id	ELV009877355
dewey-sort	3610
id	ELV03593039X
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV03593039X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625210057.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.diagmicrobio.2017.02.020</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017012000021.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV03593039X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0732-8893(17)30076-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.30</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Pfaller, M.A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013–2014)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372 Stenotrophomonas maltophilia were collected from Western Europe (WEU; n =10,021), Eastern Europe (EEU; n =4957), and the Asia-Pacific region (APAC; n =3408 [1052 from China]) in 2013–2014 as part of the SENTRY Antimicrobial Surveillance Program and tested by a reference broth microdilution method for susceptibility against tigecycline, cefoperazone/sulbactam, and comparator agents. Overall, 95.3% of Enterobacteriaceae were susceptible (≤1μg/mL; EUCAST) to tigecycline (MIC50/90, 0.12/1μg/mL) with regional EUCAST susceptibility rates of 94.8–97.8% (98.9–99.6% inhibited at ≤2μg/mL [US FDA]). Among Acinetobacter spp., 66.1% (EEU) and 79.5% (WEU) were inhibited at ≤1μg/mL of tigecycline (94.9% and 97.3% inhibited at ≤2μg/mL; pan-European MIC50/90, 1/2μg/mL). For S. maltophilia, 65.4% (China) to 88.9% (EEU) of the isolates were inhibited at ≤1μg/mL of tigecycline. Cefoperazone/sulbactam inhibited 94.6/83.5/91.5% of Enterobacteriaceae at ≤16μg/mL in WEU/EEU/APAC, respectively.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372 Stenotrophomonas maltophilia were collected from Western Europe (WEU; n =10,021), Eastern Europe (EEU; n =4957), and the Asia-Pacific region (APAC; n =3408 [1052 from China]) in 2013–2014 as part of the SENTRY Antimicrobial Surveillance Program and tested by a reference broth microdilution method for susceptibility against tigecycline, cefoperazone/sulbactam, and comparator agents. Overall, 95.3% of Enterobacteriaceae were susceptible (≤1μg/mL; EUCAST) to tigecycline (MIC50/90, 0.12/1μg/mL) with regional EUCAST susceptibility rates of 94.8–97.8% (98.9–99.6% inhibited at ≤2μg/mL [US FDA]). Among Acinetobacter spp., 66.1% (EEU) and 79.5% (WEU) were inhibited at ≤1μg/mL of tigecycline (94.9% and 97.3% inhibited at ≤2μg/mL; pan-European MIC50/90, 1/2μg/mL). For S. maltophilia, 65.4% (China) to 88.9% (EEU) of the isolates were inhibited at ≤1μg/mL of tigecycline. Cefoperazone/sulbactam inhibited 94.6/83.5/91.5% of Enterobacteriaceae at ≤16μg/mL in WEU/EEU/APAC, respectively.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Flamm, R.K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Duncan, L.R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mendes, R.E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jones, R.N.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sader, H.S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Rodrigues, Jéssica S. ELSEVIER</subfield><subfield code="t">Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications</subfield><subfield code="d">2023</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV009877355</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:88</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:177-183</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.diagmicrobio.2017.02.020</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.80</subfield><subfield code="j">Makromolekulare Chemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.30</subfield><subfield code="j">Biotechnologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">88</subfield><subfield code="j">2017</subfield><subfield code="e">2</subfield><subfield code="h">177-183</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
author	Pfaller, M.A.
spellingShingle	Pfaller, M.A. ddc 610 ddc 540 fid BIODIV bkl 35.80 bkl 58.30 Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013–2014)
authorStr	Pfaller, M.A.
ppnlink_with_tag_str_mv	@@773@@(DE-627)ELV009877355
format	electronic Article
dewey-ones	610 - Medicine & health 540 - Chemistry & allied sciences 570 - Life sciences; biology
delete_txt_mv	keep
author_role	aut
collection	elsevier
remote_str	true
illustrated	Not Illustrated
topic_title	610 610 DE-600 540 570 VZ BIODIV DE-30 fid 35.80 bkl 58.30 bkl Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013–2014)
topic	ddc 610 ddc 540 fid BIODIV bkl 35.80 bkl 58.30
topic_unstemmed	ddc 610 ddc 540 fid BIODIV bkl 35.80 bkl 58.30
topic_browse	ddc 610 ddc 540 fid BIODIV bkl 35.80 bkl 58.30
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	zu
author2_variant	r f rf l d ld r m rm r j rj h s hs
hierarchy_parent_title	Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications
hierarchy_parent_id	ELV009877355
dewey-tens	610 - Medicine & health 540 - Chemistry 570 - Life sciences; biology
hierarchy_top_title	Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)ELV009877355
title	Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013–2014)
ctrlnum	(DE-627)ELV03593039X (ELSEVIER)S0732-8893(17)30076-7
title_full	Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013–2014)
author_sort	Pfaller, M.A.
journal	Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications
journalStr	Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology 500 - Science
recordtype	marc
publishDateSort	2017
contenttype_str_mv	zzz
container_start_page	177
author_browse	Pfaller, M.A.
container_volume	88
physical	7
class	610 610 DE-600 540 570 VZ BIODIV DE-30 fid 35.80 bkl 58.30 bkl
format_se	Elektronische Aufsätze
author-letter	Pfaller, M.A.
doi_str_mv	10.1016/j.diagmicrobio.2017.02.020
dewey-full	610 540 570
title_sort	antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 gram-negative organisms from europe and the asia-pacific region (2013–2014)
title_auth	Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013–2014)
abstract	A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372 Stenotrophomonas maltophilia were collected from Western Europe (WEU; n =10,021), Eastern Europe (EEU; n =4957), and the Asia-Pacific region (APAC; n =3408 [1052 from China]) in 2013–2014 as part of the SENTRY Antimicrobial Surveillance Program and tested by a reference broth microdilution method for susceptibility against tigecycline, cefoperazone/sulbactam, and comparator agents. Overall, 95.3% of Enterobacteriaceae were susceptible (≤1μg/mL; EUCAST) to tigecycline (MIC50/90, 0.12/1μg/mL) with regional EUCAST susceptibility rates of 94.8–97.8% (98.9–99.6% inhibited at ≤2μg/mL [US FDA]). Among Acinetobacter spp., 66.1% (EEU) and 79.5% (WEU) were inhibited at ≤1μg/mL of tigecycline (94.9% and 97.3% inhibited at ≤2μg/mL; pan-European MIC50/90, 1/2μg/mL). For S. maltophilia, 65.4% (China) to 88.9% (EEU) of the isolates were inhibited at ≤1μg/mL of tigecycline. Cefoperazone/sulbactam inhibited 94.6/83.5/91.5% of Enterobacteriaceae at ≤16μg/mL in WEU/EEU/APAC, respectively.
abstractGer	A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372 Stenotrophomonas maltophilia were collected from Western Europe (WEU; n =10,021), Eastern Europe (EEU; n =4957), and the Asia-Pacific region (APAC; n =3408 [1052 from China]) in 2013–2014 as part of the SENTRY Antimicrobial Surveillance Program and tested by a reference broth microdilution method for susceptibility against tigecycline, cefoperazone/sulbactam, and comparator agents. Overall, 95.3% of Enterobacteriaceae were susceptible (≤1μg/mL; EUCAST) to tigecycline (MIC50/90, 0.12/1μg/mL) with regional EUCAST susceptibility rates of 94.8–97.8% (98.9–99.6% inhibited at ≤2μg/mL [US FDA]). Among Acinetobacter spp., 66.1% (EEU) and 79.5% (WEU) were inhibited at ≤1μg/mL of tigecycline (94.9% and 97.3% inhibited at ≤2μg/mL; pan-European MIC50/90, 1/2μg/mL). For S. maltophilia, 65.4% (China) to 88.9% (EEU) of the isolates were inhibited at ≤1μg/mL of tigecycline. Cefoperazone/sulbactam inhibited 94.6/83.5/91.5% of Enterobacteriaceae at ≤16μg/mL in WEU/EEU/APAC, respectively.
abstract_unstemmed	A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372 Stenotrophomonas maltophilia were collected from Western Europe (WEU; n =10,021), Eastern Europe (EEU; n =4957), and the Asia-Pacific region (APAC; n =3408 [1052 from China]) in 2013–2014 as part of the SENTRY Antimicrobial Surveillance Program and tested by a reference broth microdilution method for susceptibility against tigecycline, cefoperazone/sulbactam, and comparator agents. Overall, 95.3% of Enterobacteriaceae were susceptible (≤1μg/mL; EUCAST) to tigecycline (MIC50/90, 0.12/1μg/mL) with regional EUCAST susceptibility rates of 94.8–97.8% (98.9–99.6% inhibited at ≤2μg/mL [US FDA]). Among Acinetobacter spp., 66.1% (EEU) and 79.5% (WEU) were inhibited at ≤1μg/mL of tigecycline (94.9% and 97.3% inhibited at ≤2μg/mL; pan-European MIC50/90, 1/2μg/mL). For S. maltophilia, 65.4% (China) to 88.9% (EEU) of the isolates were inhibited at ≤1μg/mL of tigecycline. Cefoperazone/sulbactam inhibited 94.6/83.5/91.5% of Enterobacteriaceae at ≤16μg/mL in WEU/EEU/APAC, respectively.
collection_details	GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA
container_issue	2
title_short	Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013–2014)
url	https://doi.org/10.1016/j.diagmicrobio.2017.02.020
remote_bool	true
author2	Flamm, R.K. Duncan, L.R. Mendes, R.E. Jones, R.N. Sader, H.S.
author2Str	Flamm, R.K. Duncan, L.R. Mendes, R.E. Jones, R.N. Sader, H.S.
ppnlink	ELV009877355
mediatype_str_mv	z
isOA_txt	false
hochschulschrift_bool	false
author2_role	oth oth oth oth oth
doi_str	10.1016/j.diagmicrobio.2017.02.020
up_date	2024-07-06T18:51:00.673Z
_version_	1803856758097051648
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV03593039X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625210057.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.diagmicrobio.2017.02.020</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017012000021.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV03593039X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0732-8893(17)30076-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.30</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Pfaller, M.A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013–2014)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372 Stenotrophomonas maltophilia were collected from Western Europe (WEU; n =10,021), Eastern Europe (EEU; n =4957), and the Asia-Pacific region (APAC; n =3408 [1052 from China]) in 2013–2014 as part of the SENTRY Antimicrobial Surveillance Program and tested by a reference broth microdilution method for susceptibility against tigecycline, cefoperazone/sulbactam, and comparator agents. Overall, 95.3% of Enterobacteriaceae were susceptible (≤1μg/mL; EUCAST) to tigecycline (MIC50/90, 0.12/1μg/mL) with regional EUCAST susceptibility rates of 94.8–97.8% (98.9–99.6% inhibited at ≤2μg/mL [US FDA]). Among Acinetobacter spp., 66.1% (EEU) and 79.5% (WEU) were inhibited at ≤1μg/mL of tigecycline (94.9% and 97.3% inhibited at ≤2μg/mL; pan-European MIC50/90, 1/2μg/mL). For S. maltophilia, 65.4% (China) to 88.9% (EEU) of the isolates were inhibited at ≤1μg/mL of tigecycline. Cefoperazone/sulbactam inhibited 94.6/83.5/91.5% of Enterobacteriaceae at ≤16μg/mL in WEU/EEU/APAC, respectively.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372 Stenotrophomonas maltophilia were collected from Western Europe (WEU; n =10,021), Eastern Europe (EEU; n =4957), and the Asia-Pacific region (APAC; n =3408 [1052 from China]) in 2013–2014 as part of the SENTRY Antimicrobial Surveillance Program and tested by a reference broth microdilution method for susceptibility against tigecycline, cefoperazone/sulbactam, and comparator agents. Overall, 95.3% of Enterobacteriaceae were susceptible (≤1μg/mL; EUCAST) to tigecycline (MIC50/90, 0.12/1μg/mL) with regional EUCAST susceptibility rates of 94.8–97.8% (98.9–99.6% inhibited at ≤2μg/mL [US FDA]). Among Acinetobacter spp., 66.1% (EEU) and 79.5% (WEU) were inhibited at ≤1μg/mL of tigecycline (94.9% and 97.3% inhibited at ≤2μg/mL; pan-European MIC50/90, 1/2μg/mL). For S. maltophilia, 65.4% (China) to 88.9% (EEU) of the isolates were inhibited at ≤1μg/mL of tigecycline. Cefoperazone/sulbactam inhibited 94.6/83.5/91.5% of Enterobacteriaceae at ≤16μg/mL in WEU/EEU/APAC, respectively.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Flamm, R.K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Duncan, L.R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mendes, R.E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jones, R.N.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sader, H.S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Rodrigues, Jéssica S. ELSEVIER</subfield><subfield code="t">Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications</subfield><subfield code="d">2023</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV009877355</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:88</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:177-183</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.diagmicrobio.2017.02.020</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.80</subfield><subfield code="j">Makromolekulare Chemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.30</subfield><subfield code="j">Biotechnologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">88</subfield><subfield code="j">2017</subfield><subfield code="e">2</subfield><subfield code="h">177-183</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
score	7.399585

Nicht das Richtige dabei?

Schreiben Sie uns!

Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013–2014)

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?